Teriflunomide

Teriflunomide

SCHEMBL22661

C/C(O)=C(\C#N)C(=O)Nc1ccc(C(F)(F)F)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

DHODH

The experimentally established mechanism targets of Teriflunomide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
DHODH known ✓ Q02127 9/20 1.00
EPHX2 P34913 1/20 0.51
TRPV1 Q8NER1 1/20 0.50
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
ALDH1A1 P00352 2/20 0.48
MEN1 O00255 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
GAA P10253 1/20 0.47
CYP2C9 P11712 1/20 0.47
PKM P14618 1/20 0.47
ALOX15 P16050 1/20 0.47
TSHR P16473 1/20 0.47
KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Teriflunomide SCHEMBL993119 1.00 DHODH (1.00) DHODHEPHX2TRPV1NPC1RAB9A
Teriflunomide SCHEMBL2760666 1.00 DHODH (1.00) DHODHEPHX2TRPV1NPC1RAB9A
Teriflunomide SCHEMBL20214092 1.00 DHODH (1.00) DHODHEPHX2TRPV1NPC1RAB9A
Teriflunomide SCHEMBL8466730 0.99 DHODH (0.97) DHODHEPHX2TRPV1NPC1RAB9A
Teriflunomide SCHEMBL991312 0.99 DHODH (0.97) DHODHEPHX2TRPV1NPC1RAB9A
Teriflunomide SCHEMBL992140 0.99 DHODH (0.97) DHODHEPHX2TRPV1NPC1RAB9A
SCHEMBL9079302 0.92 DHODH (0.85) DHODHEPHX2TRPV1
SCHEMBL8808801 0.92 DHODH (0.85) DHODHEPHX2TRPV1
SCHEMBL12312432 0.90 DHODH (0.82) DHODHALDH1A1MEN1CYP1A2CYP3A4
SCHEMBL8404982 0.88 DHODH (0.79) DHODHEPHX2TRPV1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 9053 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138987-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CONTINEUM THERAPEUTICS INC (US) 2026-05-21 US claimed
WO-2026107075-A1 METHODS OF TREATING MULTIPLE SCLEROSIS WITH CD19-CD20 DUAL CAR-T CELLS GENENTECH, INC. (US) 2026-05-21 WO claimed
US-20260138973-A1 SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE SITRYX THERAPEUTICS LTD (GB) 2026-05-21 US claimed
US-20260137680-A1 NOVEL COMPOUNDS SITRYX THERAPEUTICS LTD (GB) 2026-05-21 US claimed
US-12629363-B2 Prophylaxis and treatment of angioedema PHARVARIS GMBH (CH) 2026-05-19 US claimed
US-12617762-B2 Carboxy derivatives with antiinflamatory properties SITRYX THERAPEUTICS LIMITED (GB) 2026-05-05 US claimed
US-20260108501-A1 PHARMACEUTICAL COMBINATION COMPRISING PONESIMOD VANDA PHARMACEUTICALS INC (US) 2026-04-23 US claimed
US-20260097039-A1 METHODS FOR TREATING A FATTY LIVER DISEASE MADRIGAL PHARMACEUTICALS INC (US) 2026-04-09 US claimed
US-20260085061-A1 PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS SITRYX THERAPEUTICS LIMITED (GB) 2026-03-26 US claimed
EP-4087577-B1 TREATMENT OF MEMBRANOUS NEPHROPATHY, IGG4-RELATED DISEASE, AND ANTIPHOSPHOLIPID SYNDROME USING BTK INHIBITOR 2-[(3R)-3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4-METHYL-4-[4-(OXETAN-3-YL)PIPERAZIN-1-YL]PENT-2-ENENITRILE PRINCIPIA BIOPHARMA INC (US) 2026-03-25 EP claimed
US-5532259-A ANTITUMOR HOECHST AKTIENGESELLSCHAFT (DE) 1996-07-02 US claimed
US-5519042-A Method of treating hyperproliferative vascular disease HOECHST AKTIENGESELLSCHAFT (DE) 1996-05-21 US claimed
US-5504084-A N-(4-TRIFLUOROMETHYLPHENYL) SUBSTITUTION ON 5-METHYL-ISOXAZOLE-4-CARBOXAMIDE OR 2-CYANO-3-HYDROXYCROTONAMIDE HOECHST AKTIENGESELLSCHAFT (DE) 1996-04-02 US claimed
US-5494911-A TREATING LEUKEMIA, SARCOMA, CARCINOMA, LYMPHOMA, SKIN CANCER HOECHST AKTIENGESELLSCHAFT (DE) 1996-02-27 US claimed
US-5459163-A Treatment of lupus, graft-versus-host diseases HOECHST AKTIENGESELLSCHAFT (DE) 1995-10-17 US claimed
EP-0665013-A1 Method of treating hyperproliferative vascular disease HOECHST AKTIENGESELLSCHAFT (DE) 1995-08-02 EP claimed
WO-1994024095-A1 IMMUNOSUPPRESSIVE AGENTS ABBOTT LABORATORIES (US) 1994-10-27 WO claimed
EP-0617959-A1 Pharmaceutical for the treatment of skin disorders HOECHST AKTIENGESELLSCHAFT (DE) 1994-10-05 EP claimed
EP-0527736-A1 ISOXAZOLE-4-CARBOXAMIDES AND HYDROXYALKYLIDENE-CYANOACETAMIDES, DRUGS CONTAINING THESE COMPOUNDS AND USE OF SUCH DRUGS. HOECHST AG (DE) 1993-02-24 EP claimed
WO-1991017748-A1 ISOXAZOLE-4-CARBOXAMIDES AND HYDROXYALKYLIDENE-CYANOACETAMIDES, DRUGS CONTAINING THESE COMPOUNDS AND USE OF SUCH DRUGS HOECHST AKTIENGESELLSCHAFT (DE) 1991-11-28 WO claimed